Development of Monoclonal Antibodies for the Study of Mycobacterium tuberculosis (Mtb) in the Guinea Pig

用于研究豚鼠结核分枝杆菌 (Mtb) 的单克隆抗体的开发

• 批准号: 10933281
• 负责人: MARLA POPOV
• 金额: $ 60万
• 依托单位: GLYCOSCIENTIFIC, LLC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10933281
• 关键词: Antibodies; Antigens; Cavia; Development; Disease; Generations; Immune Sera; Immune response; Immunization; Immunologic Markers; Immunologics; Inflammatory; Modeling; Monoclonal Antibodies; Mycobacterium tuberculosis; Oryctolagus cuniculus; Preparation; Production; Reagent; Tuberculosis; cytokine; response; screening; transmission process

GlycoScientific proposes to generate antibodies specific for six inflammatory cytokines to elucidate and correlate immunological markers of tuberculosis (TB) transmission and disease development in the guinea pig. Once the antibodies are produced, the Offeror will use them to evaluate the cytokines in TB infected and non-infected guinea pigs. The production of these crucial immunological reagents will greatly enhance our understanding of basic immune responses to TB infection in naturally infected mammalian models.

GlycoScience公司建议产生针对6种炎性细胞因子的抗体，以阐明和关联结核病(TB)在豚鼠中传播和疾病发展的免疫标记物。一旦产生抗体，出资人将使用它们来评估感染结核病和未感染的豚鼠体内的细胞因子。这些关键免疫学试剂的生产将极大地提高我们对自然感染哺乳动物模型中结核病感染的基本免疫反应的理解。